Profile data is unavailable for this security.
About the company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
- Revenue in USD (TTM)4.74bn
- Net income in USD1.36bn
- LocationAlexion Pharmaceuticals Inc121 Seaport BlvdBOSTON 02210-2050United StatesUSA
- Phone+1 (475) 230-2596
- Fax+1 (203) 271-8198
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|ALXN:NSQ since |
|Achillion Pharmaceuticals Inc||Announced||16 Oct 2019||16 Oct 2019Announced||2.21%||1.23bn|